PancreaCell Unveils Total Pancreas Regeneration Device Ahead of ADA

http://photos.prnewswire.com/prnh/20160610/377988

The PancreaCell micro stimulator uses precise bioelectric signaling to control release of 10 key organ regeneration proteins and signals for also controlling stem cell recruitment, proliferation and differentiation. The stimulator is complimented by an implantable, programmable, re-fillable micro infusion pump. The micro pump is used to deliver PancreaCell's proprietary PC-15 stem cell based regenerative cocktail once a week over a 36-month course of total organ regeneration treatment. This proprietary composition includes a variety of modified cells including mesenchymal stem cells from bone marrow, umbilical cord derived cells, neurogenin 3⁺ progenitor cells and adipose (fat) derived cells, a variety of growth factors including developmental morphogen proteins known as hedgehogs, islet homeostasis protein (IHoP), M2 macrophages, selected micro RNAs, BMP-7, PDLI, pancreatic derived matrix and nutrient hydrogel. The therapy is complimented by delivery of auto-immune and anti-inflammatory agents such as highly purified Omega 3 fatty acids. The PancreaCell regeneration stimulator + micro pump device is implanted in a patient's abdomen with a pacing infusion lead directed to the center of the pancreas fixated with a special soft tissue fixation tip. The re-filling silicon septum port for the micro pump is easily accessible for weekly re-fills of the PC-15 regenerative cocktail composition.

The company will hold a conference call during the American Diabetes Association (ADA) Annual Meeting Monday June 13th at 4:30pm EST/1:30pm PST to answer any questions reporters may have:

Monday, June 13th, 4:30pm EST
Call in Number: (712) 775-7031
Access Code:  405-822-417

The company has designed a clinical protocol that it plans to launch later this year after pre-clinical safety studies have been completed. A copy of the proposed clinical study protocol may be viewed here - http://leonhardtventures.com/pancreacell/#toggle-id-1

"I have been following this development for years and believe if it works as intended it will completely change the course of treatment for millions of patients suffering of diabetes."  states Dr. Camillo Ricordi, Director of the Diabetes Research Institute at the University of Miami and an advisor to the company.

"Numerous studies have already been conducted documenting the safety and efficacy of many of the individual components of the PancreaCell therapy, such as IGF-1, HGF and stem cells, in one-time delivery, but no studies have been conducted with all 10 protein expression stimulation signals administered multiple times daily and all 15 components of our proprietary PC-15 regenerative cocktail infused once a week directly into the pancreas."  stated Howard Leonhardt, PancreaCell Executive Chairman. "We look forward to implementing carefully designed clinical trials with leading centers."

The company announced last month the filing of a provisional patent application for special bioelectric signals designed to stop cancer tumor growth by stopping cell division and blood supply which may be used to treat pancreatic cancer in a presumably less toxic way than chemo or radiation and with the benefit of a full regeneration program to follow eradication of the tumors -http://mysocialgoodnews.com/leonhardt-ventures-cerebracell-file-patent-application-bioelectric-signals-halt-tumor-growth-regenerate-organs/

Dr. Jorge Genovese of the University of Buenos Aires and Howard Leonhardt are the co-inventors of this device and composition.

About PancreaCell: PancreaCell formed in 2015 is a spin out of the work Leonhardt Ventures has been leading since the 1980's in heart and cardiovascular regeneration research. PancreaCell incubates at the Cal-X Stars Business Accelerator www.calxstars.com in Santa Monica, CA and the newly formed Leonhardt's Launchpads Utah research laboratories in Salt Lake City, Utah. Web Site - http://leonhardtventures.com/pancreacell/

About Leonhardt Ventures: Leonhardt Ventures (Leonhardt Vineyards LLC DBA Leonhardt Ventures - formerly HJ Leonhardt & Co.) has been developing and bringing to market cardiovascular and organ repair and regeneration devices since 1982. Over 21 issued U.S. patents and dozens more pending or in process have been the foundation of launching over 33 startups mostly in the cardiovascular and regenerative medtech space.   The team developed the leading predictably compliant cardiovascular balloon catheters in the 1980's, the leading stent graft and first percutaneous heart valve in the 1990's, and the first muscle stem cell therapy for treating heart failure in the 2000's. Web Site - www.leonhardtventures.com;

Contact:
Howard J. Leonhardt
PancreaCell, a Leonhardt Ventures Co.
1531 6th Street, Unit 401, Santa Monica, CA  90401
email 
phone 310 310 2534

SOURCE PancreaCell